Hybridoma screening
Hybridoma screening
Hybridoma technology is key to producing large numbers of monoclonal antibodies. Screening by ELISA uses costly reagents and is time-consuming, and protein microarray offers a reliable high-throughput solution.
Selected publications
High-throughput hybridoma screening
A. Sawyer and D. Hall
Genetic Engineering and Biotechnology News
New monoclonal antibodies to defined cell surface proteins on human pluripotent stem cells
C. M. O'Brien, H. S. Chy, Q. Zhou, S. Blumenfeld, J. W. Lambshead, X. Liu, J. Kie, B. D. Capaldo, T. Chung, T. E. Adams, T. Phan, J. D. Bentley, W. J. McKinstry, K. Oliva, P. J. McMurrick, Y. Wang, F. J. Rossello, G. J. Lindeman, D. Chen, T, Jarde, A. T. Clark, H. E. Abud, J. E. Visvader, C. M. Nefzger, J. M. Polo, J. F. Loring, and A. L. Laslett
Stem Cells
Testimonials
"We are very pleased to be working with Arrayjet, as we see high throughput inkjet technology as very much the future of protein microarraying. The Super-Marathon enables us to do things that are simply not possible with a pin spotter, and we've given it pride of place in our new, highly automated facility."
Alan Sawyer, previous Director at EMBL Monoclonal Core Facility